A Randomized, Active-Controlled, Double-Masked, Crossover Study to Evaluate the Clinical Performance of Deseyne (Vifilcon C) Daily Disposable Soft Contact Lens for Presbyopia Extended Depth of Focus (EDOF)
CompletedNAResults postedLast updated 17 March 2026
What this trial tests
NA trial testing Test lens in Presbyopia Condition in 78 participants. Completed in 15 January 2025.
Adults 45 to 70, any sex, with Presbyopia Condition. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
The Primary Effectiveness Endpoint for the Study is Monocular (Study [Right] Eye Only) Photopic Negative Lens-induced Distance-corrected Depth of Focus (DOF) at the 0.2 logMAR VA Threshold.Primary· Day 1
The primary effectiveness endpoint for the study is monocular (study \[right\] eye only) photopic negative lens-induced distance-corrected depth of focus (DOF) at the 0.2 logMAR VA threshold.. This is accomplished by adding small incremental negative lens power over the distance best corrected vision correction until blurred vision is determined (study eye only).
Group
Value
95% CI
Test
-2.22
± 0.774
Control
-1.44
± 0.672
Mean Monocular (Study Eye Only) Photopic Distance-corrected Intermediate Visual Acuity (DCIVA) at 66 cmSecondary· Day 1
Method defines measurement of visual acuity through the distance correction contact lens measured at a distance of 66 cm from the patient.
Group
Value
95% CI
Test
0.015
± 0.1135
Control
0.158
± 0.1360
Mean Monocular (Study Eye Only) Photopic Distance-corrected Near Visual Acuity (DCNVA) at 40 cmSecondary· Day 1
Method is to test visual acuity through the distance contact lens correction at 40cm from the patient.
Group
Value
95% CI
Test
0.196
± 0.1145
Control
0.353
± 0.1707
Sponsor's own description
The goal of this clinical trial is to learn if the contact lens we are testing will work to extend the range of clear focus at distance to provide an increase in clear vision at closer ranges without the additional need for bifocal lenses or reading correction.
The clinical study will compare the use of the test lens for extended range of focus (far to near) to a standardized contact lens designed for distance vision (far) (ie. Walking, driving, etc., where closer-in vision is not anticipated to be helpful, particularly in a population of users in the age range of 45-70.
We will also learn about the effectiveness of the lens to maintain good contrast in low illumination such as during evening and night-time periods.
The main questions we aim to address in the study are:
\*. Does the contact lens provide adequate vision at distances closer to the patient such as during reading or computer usage?
\* Whether the contact lens in use introduces any visual disturbance or safety concern as compared to a currently designed lens for distance use?
The study is designed to be conducted in the doctor's office:
* Using electronic vision measuring equipment familiar to the user.
* A total of two visits are necessary to complete he study
* All patients will experience using the test lens as well as the control lens during the study
* No contâct lenses will be given to the study patients to take home.
* It is anticipated that the total amount of time of participation in the study will be approximately 3 hours of your time over two separate visits.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bruno Vision Care
Last refreshed: 17 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06698731.